Life sciences

Apellis Announces U.S. Food and Drug Administration (FDA) Approval of EMPAVELI™ (pegcetacoplan) for Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Pharmaceutical industry, PNH, XE-class submarine, Medication package insert, Boxed warning, Health sciences, Health, Life sciences

Friday, May 14, 2021 - 11:25pm

\xe2\x80\x9cThrough my work as an investigator on the PEGASUS study, I was excited to see EMPAVELI providing broad control of PNH.

Key Points:

\xe2\x80\x9cThrough my work as an investigator on the PEGASUS study, I was excited to see EMPAVELI providing broad control of PNH.
\xe2\x80\x9cThis approval represents a major scientific advancement as EMPAVELI ushers in the first new class of complement medicine in almost 15 years.
\xe2\x80\x9cMany PNH patients are seeking choices in their treatment, so the approval brings new promise for the PNH community.\xe2\x80\x9d\nThe prescribing information for EMPAVELI contains a boxed warning.
ApellisAssist\xe2\x84\xa2 is a program designed to provide comprehensive product support to EMPAVELI patients throughout their treatment journey.

Gilead Sciences to Present at Upcoming Investor Conferences

Professional services, Health, Hospitals, Finance, General Health, Pharmaceutical, Biotechnology, Specialty drugs, Biotechnology, Gilead Sciences, Life sciences, Pharmaceutical industry

Friday, May 14, 2021 - 9:05pm

b'Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:\nCowen Annual Virtual Oncology Innovation Summit on Friday, May 21 at 12:00pm ET\nJefferies Virtual Healthcare Conference on Tuesday, June 1 at 1:30pm ET\nBernstein Annual Strategic Decisions Conference on Wednesday, June 2 at 4:30pm ET\nGoldman Sachs Annual Global Healthcare Conference on Wednesday, June 9 at 2:10pm ET\nThe live webcasts can be accessed at the company\xe2\x80\x99s investors page at investors.gilead.com.

Key Points:

b'Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:\nCowen Annual Virtual Oncology Innovation Summit on Friday, May 21 at 12:00pm ET\nJefferies Virtual Healthcare Conference on Tuesday, June 1 at 1:30pm ET\nBernstein Annual Strategic Decisions Conference on Wednesday, June 2 at 4:30pm ET\nGoldman Sachs Annual Global Healthcare Conference on Wednesday, June 9 at 2:10pm ET\nThe live webcasts can be accessed at the company\xe2\x80\x99s investors page at investors.gilead.com.
The replays will be available for at least 30 days following the presentation.\nGilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people.
The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer.
Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.\nFor more information on Gilead Sciences, please visit the company\xe2\x80\x99s website at www.gilead.com , follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210514005524/en/\n'

Noble Capital Markets and Channelchek to Host Investor Forum C-Suite Interviews During Prestigious 16th Annual World Stem Cell Summit

Branches of biology, Biology, Life sciences, XC2, Bernard Siegel, Stem cell

Friday, May 14, 2021 - 7:42pm

b'BOCA RATON, Fla., May 14, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Noble Capital Markets (\xe2\x80\x9cNoble\xe2\x80\x9d), a research-driven investment bank, today announces its platinum-level sponsorship of, and collaboration with, the 16th World Stem Cell Summit, to be held virtually June 14-18, 2021.

Key Points:

b'BOCA RATON, Fla., May 14, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Noble Capital Markets (\xe2\x80\x9cNoble\xe2\x80\x9d), a research-driven investment bank, today announces its platinum-level sponsorship of, and collaboration with, the 16th World Stem Cell Summit, to be held virtually June 14-18, 2021.
\xc2\xa0\xe2\x80\x9cIt is our passion at Noble, and we\xe2\x80\x99re extremely excited to serve as the\xc2\xa0principal partner of the Investor Forum track at the Summit.\xe2\x80\x9d\nBernard Siegel, executive director of RMF and founder of the World Stem Cell Summit, said, \xe2\x80\x9cThere is huge investor interest in the regenerative medicine and longevity space.
As with all other content on Channelchek, there will be no cost to access these ChannelCasts.\nFor more information and to register for the Investor Forum and other events at the World Stem Cell Summit,\xc2\xa0please visit: https://ibn.fm/WorldStemCellSummit2021 .
In 2005, Noble established NobleCon, an investor conference that has grown substantially over the last decade and a half.

Jinfiniti and Takezo team to provide smart consumers precision health

Biology, Branches of biology, Biomarkers, Life sciences

Friday, May 14, 2021 - 6:00pm

To address this need, Augusta, Ga.-based biomarker tester Jinfiniti Precision Medicine and Portland-based supplement provider Takezo have come together to offer consumers a curated shopping experience based on their biomarker data.\nThrough this newfound partnership, consumers can take a biomarker test provided by Jinfiniti.

Key Points:

To address this need, Augusta, Ga.-based biomarker tester Jinfiniti Precision Medicine and Portland-based supplement provider Takezo have come together to offer consumers a curated shopping experience based on their biomarker data.\nThrough this newfound partnership, consumers can take a biomarker test provided by Jinfiniti.
By assessing certain biomarkers, the test is intended to show consumers where their bodies need attention the most.
The results are then sent (with consumer consent) to Takezo, which will curate a bundle of products that address the consumers\' biomarker weaknesses.
As a result, this personalized selection of nutrition helps consumers make educated health decisions and streamlines the shopping process at the same time.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against FibroGen Inc. (FGEN)

Enzymes, Life sciences, Biotechnology, Acetic acids, Isoquinolines, Roxadustat, Hypoxia-inducible factor, Hydroxylation, Procollagen-proline dioxygenase, Biopharmaceutical

Friday, May 14, 2021 - 5:00pm

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn more about your rights.\nFibroGen is a biopharmaceutical company that develops medicines for the treatment of anemia, fibrotic disease, and cancer.

Key Points:

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn more about your rights.\nFibroGen is a biopharmaceutical company that develops medicines for the treatment of anemia, fibrotic disease, and cancer.
Its most advanced product is roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor-prolyl hydroxylase (\xe2\x80\x9cHIF-PH\xe2\x80\x9d) activity that acts by stimulating the body\xe2\x80\x99s natural pathway for red cell production.
To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
If you inquire by email please include your mailing address, telephone number and number of shares purchased.\nThis press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.\nGlancy Prongay & Murray LLP, Los Angeles\n'

2021 Growth Opportunities in Cell & Gene Therapies, Retinal Diseases, Drug Delivery Platforms, Plant-based Drugs, Cardiac Health, AI-based Devices, Computation Methods, and Cultured Milk - ResearchAndMarkets.com

Biotechnology, Pharmaceutical, Genetics, Health, Biotechnology, Articles, Emerging technologies, Branches of biology, Life sciences, Nanomedicine, Personalized medicine, Gene therapy

Friday, May 14, 2021 - 4:25pm

b'The "2021 Growth Opportunities in Cell & Gene Therapies, Retinal Diseases, Drug Delivery Platforms, Plant-based Drugs, Cardiac Health, AI-based Devices, Computation Methods, and Cultured Milk" report has been added to ResearchAndMarkets.com\'s offering.\nThis edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides insights across retinal diseases, viral and non-viral vector platforms for gene therapies, allogeneic cell therapy, bone repair, gluten antigen-specific drug therapy for Celiac disease, plant-based anti-cancer agents, and food colors.

Key Points:

b'The "2021 Growth Opportunities in Cell & Gene Therapies, Retinal Diseases, Drug Delivery Platforms, Plant-based Drugs, Cardiac Health, AI-based Devices, Computation Methods, and Cultured Milk" report has been added to ResearchAndMarkets.com\'s offering.\nThis edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) provides insights across retinal diseases, viral and non-viral vector platforms for gene therapies, allogeneic cell therapy, bone repair, gluten antigen-specific drug therapy for Celiac disease, plant-based anti-cancer agents, and food colors.
Further, PCR-free whole genome sequencing, oral protein-drug delivery technology for insulin, and cryo transmission electron microscope for viral protein analysis are discussed.\nThe Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry.
The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.\nThe Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.\n'

Cytovia Therapeutics CEO Dr. Daniel Teper to Present at Two Upcoming Conferences

Branches of biology, Biology, Life sciences, Induced stem cells, Stem cells, Biotechnology, Lymphocytes, Immune system, IPSCS, Induced pluripotent stem cell, Natural killer cell, Cellectis

Friday, May 14, 2021 - 3:58pm

Cytovia focuses on Natural Killer (NK) cell biology and applies precision engineering to induced pluripotent stem cells (iPSCs) to develop the safest, most effective, most broadly-available off-the-shelf Natural Killer cell therapy as a first line of defense against cancer.

Key Points:

Cytovia focuses on Natural Killer (NK) cell biology and applies precision engineering to induced pluripotent stem cells (iPSCs) to develop the safest, most effective, most broadly-available off-the-shelf Natural Killer cell therapy as a first line of defense against cancer.
Cytovia\xe2\x80\x99s proprietary multi-specific antibody platform has been customized to engage and activate NK Cells at the tumor site.
Both platforms offer optionality to clinicians and can also be used synergistically.
Cytovia\xe2\x80\x99s R&D laboratories and GMP manufacturing facility are augmented by scientific partnerships with Cellectis, CytoImmune, the Hebrew University of Jerusalem, INSERM, the New York Stem Cell Foundation, STC Biologics, and the University of California San Francisco (UCSF).\n'

Atossa Therapeutics to Participate at the Investor Summit Conference and Present to Investors on May 18, 2021

Life sciences, Atossa Therapeutics, Biotechnology, Health sciences, Selective estrogen receptor modulators, Triphenylethylenes, Atossa, Biopharmaceutical, Endoxifen

Friday, May 14, 2021 - 2:00pm

b'SEATTLE, May 14, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases, today announced that management will participate at the Investor Summit Conference on May 18, 2021.\nCEO Dr. Steven Quay and Kyle Guse, CFO and General Counsel will deliver a corporate presentation at 8:45am ET on May 18, 2021.\nInvestors can also request a one-on-one meeting with management to be arranged following the conclusion of the conference.\nAtossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases, with a current focus on breast cancer and COVID-19.

Key Points:

b'SEATTLE, May 14, 2021 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases, today announced that management will participate at the Investor Summit Conference on May 18, 2021.\nCEO Dr. Steven Quay and Kyle Guse, CFO and General Counsel will deliver a corporate presentation at 8:45am ET on May 18, 2021.\nInvestors can also request a one-on-one meeting with management to be arranged following the conclusion of the conference.\nAtossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need in oncology and infectious diseases, with a current focus on breast cancer and COVID-19.
For more information, please visit www.atossatherapeutics.com\nForward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with development plans, any variation between interim, preliminary and final clinical results, actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa including those needed to commence studies of AT-H201, AT-301 and Endoxifen, lower than anticipated rate of patient enrollment, estimated market size of drugs under development, the safety and efficacy of Atossa\xe2\x80\x99s products, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others such as patent rights, whether reduction in Ki-67 or any other result from a neoadjuvant study is an approvable endpoint for oral Endoxifen, whether change in mammographic breast density is an approvable end point for oral Endoxifen, and other risks detailed from time to time in Atossa\xe2\x80\x99s filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.\n'

Catabasis Pharmaceuticals To Present At Upcoming Investor Conferences

Biotechnology, Pharmaceutical, Health, Life sciences, Medical specialties, Clinical medicine, Complement deficiency, Biotechnology, Angioedema, Catabasis Pharmaceuticals, Hereditary angioedema, Monoclonal antibody, Biopharmaceutical, QLS, Kallikrein

Friday, May 14, 2021 - 1:00pm

b'Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide information on its lead program QLS-215, which is in preclinical development for the treatment of hereditary angioedema, at the following upcoming virtual investor conferences:\nOppenheimer Rare and Orphan Disease Summit.

Key Points:

b'Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide information on its lead program QLS-215, which is in preclinical development for the treatment of hereditary angioedema, at the following upcoming virtual investor conferences:\nOppenheimer Rare and Orphan Disease Summit.
Presentations will be available on-demand on May 21, 2021.\nJefferies Virtual Healthcare Conference on June 3, 2021 at 9:30am ET.\nWebcasts of the events can be accessed from the investors section of www.catabasis.com .
Archived replays will be available for 30 days following the event.\nAt Catabasis Pharmaceuticals, our mission is to bring hope with life-changing therapies to patients and families.
Our lead program, QLS-215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210514005065/en/\n'

Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences in May

Biotechnology, General Health, Health, Pharmaceutical, Oncology, Life sciences, Biology, Branches of biology, Biotechnology, Stem cells, Cell biology, Cloning, Biopharmaceutical, Hematopoietic stem cell transplantation

Friday, May 14, 2021 - 1:00pm

b'Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced that Jason Gardner, D.Phil., President and Chief Executive Officer, will participate in fireside chats at the following investor conferences this month:\nCowen 2nd Annual Virtual Oncology Innovation Summit on Thursday, May 20, at 10:40 a.m. ET\nOppenheimer Rare & Orphan Disease Summit on Friday, May 21, at 2:55 p.m. ET\nLive webcasts of the fireside chats can be accessed on the Magenta Therapeutics website at https://investor.magentatx.com/events-and-presentations .

Key Points:

b'Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplants to more patients, today announced that Jason Gardner, D.Phil., President and Chief Executive Officer, will participate in fireside chats at the following investor conferences this month:\nCowen 2nd Annual Virtual Oncology Innovation Summit on Thursday, May 20, at 10:40 a.m. ET\nOppenheimer Rare & Orphan Disease Summit on Friday, May 21, at 2:55 p.m. ET\nLive webcasts of the fireside chats can be accessed on the Magenta Therapeutics website at https://investor.magentatx.com/events-and-presentations .
The webcast replays will be available for 90 days following each event.\nMagenta Therapeutics is a clinical-stage biotechnology company developing medicines to bring the curative power of stem cell transplant to more patients with blood cancers, genetic diseases and autoimmune diseases.
Magenta is combining leadership in stem cell biology and biotherapeutics development with clinical and regulatory expertise, a unique business model and broad networks in the stem cell transplant community to revolutionize immune reset for more patients.\nMagenta is based in Cambridge, Mass.
For more information, please visit www.magentatx.com .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210514005057/en/\n'